Management of dermatomyositis patients amidst the COVID-19 pandemic
Two case reports

Yumeng Cao, MMa, Jingrun Zhou, MMa, Tingting Cao, MMb, Guqin Zhang, MDa, Huaqin Pan, MDc,d,*

Abstract

Rationale: In December 2019, a new epidemic of coronavirus disease 2019 (COVID-19) appeared in Wuhan, Hubei Province, and spread rapidly to other parts of China and worldwide. Although established methods exist for the diagnosis and treatment of COVID-19 infection, the management of dermatomyositis (DM) patients with COVID-19 is unknown.

Patient concerns: In this article, we describe case reports of 2 patients with DM. The first case was a 67-year-old patient with DM and infected with COVID-19 who was admitted to Leishenshan Hospital for a 1-month history of fever, cough, and expectoration. The second case was a 51-year-old male patient who was admitted to Leishenshan Hospital due to fever with cough, expectoration and shortness of breath for 1 month.

Diagnoses: The first patient was diagnosed with COVID-19 secondary to DM based on repeated SARS-CoV-2 real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) test, detailed medical history and chest computed tomography; The second patient was diagnosed with interstitial lung disease associated with anti-MDA5 DM based on the results of antirheumatic and anti-inflammatory therapy and the above 3 methods.

Interventions and outcomes: The first patient received supportive and empirical treatment, including antiviral treatment, anti-inflammatory treatment, oxygen therapy and prophylactic anticoagulation therapy. The symptoms and laboratory results got improved after the treatments. He was discharged with thrice negative PCR tests for the SARS-CoV-2 virus. The second patient received a comprehensive treatment, including glucocorticoid and plasma exchange; his symptoms were relieved and improved.

Lessons: These cases suggest that repeated new pathogenic test results for the coronavirus and a detailed diagnosis of the medical history are important means to distinguish these diseases. Increased attention to the individual characteristics of different cases may allow for more effective diagnosis and treatment.

Abbreviations: COVID-19 = coronavirus disease 2019, CT = computed tomography, DM = dermatomyositis, ESR = erythrocyte sedimentation rate, GGO = ground-glass opacity, LMWH = low-molecular weight heparin, RT-PCR = real-time reverse-transcriptase polymerase-chain-reaction, SARS-COV-2 = severe acute respiratory syndrome coronavirus 2.

Keywords: case report, coronavirus, COVID-19, dermatomyositis, pandemic, SARS-CoV-2 virus

1. Introduction

In December 2019, a new epidemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared in Wuhan, Hubei Province, China. COVID-19 is highly infectious through respiratory droplets and direct and indirect contact via surfaces[1]; therefore, it spread rapidly to other parts of China and worldwide.[2] Globally, as of 6:36 pm CEST, August 12, 2022, there have been 585,950,085 confirmed cases of COVID-19, including 6,425,422 deaths.[3] The most common symptoms at the onset of illness in COVID-19 patients are respiratory compromise with fever and cough, dyspnea, myalgia, or fatigue. The most common radiologic patterns on chest computed tomography (CT) were ground-glass opacity (GGO) and bilateral patchy shadowing.[4]

VC and JZ contributed equally to this work.
Funding was not applicable for this study.
Written informed consent for publication of the clinical details and/or clinical images was obtained from the patient. Informed written consent was obtained from the patient for publication of this report and any accompanying images. All authors who have affiliations with Zhongnan Hospital of Wuhan University declare that they do not have any competing interests. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The authors have read the CARE Checklist (2013), and the manuscript was prepared and revised according to the CARE Checklist (2013). The study is approved by the Medical Ethics Committees, Zhongnan Hospital of Wuhan University (No.2020099K) and the patient provided consent to participate.
* Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China. Clinical Research Center of Hubei Critical Care Medicine, Wuhan, Hubei Province, China
Correspondence: Huaqin Pan, Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 169 Eastlake Rd., Wuchang District, Wuhan, 430071, Hubei Province, China (e-mail: phq2012@whu.edu.cn).
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Cao Y, Zhou J, Cao T, Zhang G, Pan H. Management of dermatomyositis patients amidst the COVID-19 pandemic: Two case reports. Medicine 2022;101:38(e30634).
Received: 7 June 2022 / Received in final form: 15 August 2022 / Accepted: 16 August 2022
http://dx.doi.org/10.1097/MD.0000000000030634
Dermatomyositis (DM) is a multisystem autoimmune disease caused by a complex interplay of genetics and environmental exposure with various influencing factors. Lung involvement is frequently observed in patients with DM. Dyspnea and nonproductive cough are the most common symptoms in these patients. Although there are methods for the diagnosis and treatment of COVID-19 infection, the clinical characteristics, treatment, and prognosis of patients with DM disease and those infected with COVID-19 are not well established. Here we report 2 DM cases that may provide a basis for the clinical treatment of COVID-19-infected DM patients.

2. Case presentation

2.1. Case 1

2.1.1. Chief complaints. A 67-year-old male patient living in Wuhan was admitted to Leishenshan Hospital for a 1-month history of fever, cough, and expectoration.

2.1.2. History of present illness. The patient had suffered from fever, cough, and expectoration for a month, without myalgia, dyspnea, chills, diarrhea, nausea, vomiting or hemoptysis. Before admission, the patient had been diagnosed with COVID-19 with twice positive real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) tests for the SARS-CoV-2 virus. The patient had received symptomatic supportive therapy such as oxygen inhalation, antiviral, antibacterial, cough, and phlegm relief in the local hospital. However, the patient still had a cough and sputum.

2.1.3. History of past illness. His previous medical history was DM for >1 year with the treatment of prednisone (20 mg/day).

2.1.4. Physical examination upon admission. Physical examination revealed a body temperature of 36.5°C, a blood pressure of 130/80 mm Hg, a pulse of 75 beats per minute, and a respiratory rate of 18 breaths per minute.

2.1.5. Laboratory examinations. Laboratory results were summarized as follows:

- Lymphocyte count and percentage dramatically decreased.
- Thrombocyte count mildly decreased.
- Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), D-dimer and erythrocyte sedimentation rate were noticeably elevated (Table 1).

2.1.6. Imaging examinations. The chest CT on hospital day 6 showed bilateral peripheral ground-glass opacification (GGO) (Fig. 1).

2.1.7. Further diagnostic work-up. The patient was further evaluated with blood cultures, urine, and stool cultures which turned out negative. The patient tested positive for SARS-CoV-2 virus by PCR test twice.

2.2. Final diagnosis

The final diagnosis of the presented case is COVID-19 pneumonia.

2.3. Treatment

Treatment during hospitalization was largely symptomatic and supportive. The patient was supplied with persistent low flow oxygen therapy, abidol (0.1g, twice daily, po), ribavirin (0.5g, once daily, iv), and Chinese medicine such as antiviral therapy. Moxifloxacin (0.4g, once daily, po) was also administered to prevent secondary infection, as well as diammonium glycyrrhizinate enteric-coated capsules (150mg, thrice daily, po) for liver function improvement and protection therapy and low-molecular weight heparin (LMWH) as prophylactic anticoagulation therapy. To attenuate lung inflammation, a low dose of methylprednisolone (40 mg, once daily, iv) was administered.

The patient’s symptoms continued to alleviate with active treatments. Amounts of methylprednisolone were gradually decreased.

### Table 1

| Measures                                        | Normal range | Feb. 21 Day 3 | Mar. 03 Day 14 | Mar. 13 Day 24 | Mar. 18 Day 29 |
|------------------------------------------------|--------------|---------------|----------------|----------------|---------------|
| **Laboratory examinations**                     |              |               |                |                |               |
| White blood cells, x10^9/L                      | 3.5-9.5      | 3.26          | 4.7            | NA             | 3.39          |
| Neutrophil counts, x10^9/L                      | 1.8-6.3      | 2.25          | 3.32           | 2.57           | 1.78          |
| Lymphocyte counts, x10^9/L                      | 1.1-3.2      | 0.58          | 0.77           | 0.61           | 0.99          |
| C-reactive protein, mg/L                        | 0-10.0       | -             | 5.69           | 2.96           | 1.84          |
| D-dimer, mg/L                                  | 0-500        | 8.06          | -              | 1.35           | -             |
| BUN, pg/ml                                      | 0-100        | 6.2           | 5.2            | 6.7            | 61.0          |
| Cr, μmol/L                                      | 64-104       | 66.6          | 69.5           | 72.6           | 70.9          |
| Uric acid, μmol/L                              | 208-428      | 209           | 304            | 369            | 344           |
| ESR, mm/H                                       | 0-20         | 25            | 27             | 31             | -             |
| IL-6, pg/ml                                     | 0-7          | NA            | NA             | 2.86           | -             |
| **Vital signs**                                 |              |               |                |                |               |
| Temperature, °C                                 | 36-37        | 37.9          | 36.5           | 36.6           | 36.5          |
| Pulse, beats per minute                         | 60-100       | 98            | 88             | 72             | 82            |
| Respiratory rate, breaths per minute            | 16-20        | 20            | 21             | 19             | 17            |
| Blood pressure, mmHg                            | 90-140/60-90 | 126/77        | 115/83         | 118/78         | 122/86        |

| Treatments                                      |              |               |                |                |               |
| Low flow oxygen therapy                         |              |               |                |                |               |
| Antiviral therapy (abidol, ribavirin and Chinese medicine) |          |               |                |                |               |
| Prevent secondary infection (Moxifloxacin)       |              |               |                |                |               |
| Liver function improvement and protection therapy (diammonium glycyrrhizinate enteric-coated capsules) | |               |                |                |               |
| Prophylactic anticoagulation therapy (low molecular weight heparin) | |               |                |                |               |
| Attenuate lung inflammation (methylprednisolone 40 mg, once daily, iv) | |               |                |                |               |

BUN = blood urea nitrogen, Cr = creatinine, ESR = erythrocyte sedimentation rate, IL-6 = Interleukin-6, NA = none available.
decreased and discontinued on day 11 of hospitalization. LWMH was discontinued on day 32 of hospitalization.

2.4. Outcome and follow-up
With treatment, the patient was asymptomatic aside from an intermittent dry cough. The previous GGO in both lungs was alleviated, and the results of laboratory reexamination were significantly improved. When the patient tested negative for SARS-CoV-2 virus by PCR test thrice, he was discharged and remained in quarantine for 14 days.

2.5. Case 2
2.5.1. Chief complaints. A 51-year-old man was admitted to Leishenshan Hospital due to fever with cough, expectoration, and shortness of breath for 1 month.

2.5.2. History of present illness. The patient's symptoms started a month ago. Nucleic acid detection of COVID-19 was negative in the local hospital prior to admission. He was suspected to be infected with the SARS-CoV-2 virus.

2.5.3. History of past illness. The patient was diagnosed with interstitial lung disease related to anti-MDA5 DM in November 2019 and received glucocorticoid therapy.

2.5.4. Physical examination upon admission. The physical examination revealed a body temperature of 36.8°C, a blood pressure of 116/83 mm Hg, a pulse of 124 beats per minute, a respiratory rate of 20 breaths per minute, and oxygen saturation of 94% without oxygen inhalation.

2.5.5. Laboratory examinations. Blood analysis revealed a mild leukocytosis of $3.67 \times 10^9/L$, with predominant neutrophils ($3.10 \times 10^9/L$). Serum C-reactive protein was increased at 20.63 mg/L (normal range < 8 mg/L) (Table 2).

2.5.6. Imaging examinations. Chest CT imaging showed bilateral interstitial infiltrating shadows (Fig. 1).

2.5.7. Further diagnostic work-up. The anti-MDA5 antibody was positive, and the repeated PCR test for the SARS-CoV-2 virus was negative.

2.6. Final diagnosis
The final diagnosis of the presented case is interstitial lung disease (ILD) associated with anti-MDA5 DM, rather than COVID-19 pneumonia.

2.7. Treatment
An hour and a half after admission, the patient suddenly developed dyspnea with a declining blood pressure of 88/60 mm Hg, as well as tachycardia. He was supplied immediately with rehydration, anti-shock, active vascular medicine, anti-virus, and symptomatic and supportive treatment. Subsequently, he was transferred to the intensive care unit. The risk score of deep vein thrombosis was 5 and LMWH was administered to prevent thrombosis. However, the patient's state did not improve despite active treatments. Results of the pharyngeal swab specimen, nasal swab specimen and anal swab specimen analysis by SARS-CoV-2 RT-PCR test confirmed the patient to be negative for COVID-19. The levels of anti-SS-A/Ro 52KD antibody and anti-SS-A/Ro 62KD antibody were markedly increased. The final diagnosis was IDL (severe). He was supplied with tocilizumab, glucocorticoid (80 mg, once daily, iv) and plasma exchange (Table 2). After treatments, the patient's symptoms continued to alleviate.
2.8. Outcome and follow-up
After 30 days of treatment, the results of continuous laboratory examination showed that abnormal indicators such as interleukin-6 (IL-6) returned to normal (Table 2). CT dynamic monitoring showed that symptoms were relieved and improved compared with symptoms at the time of admission (Fig. 1). The patient was discharged on April 4 and transferred to a local hospital.

3. Discussion
The lung is a frequently damaged organ of autoimmune-mediated injury in patients with DM.[5,6] DM patients with lung involvements usually present with interstitial lung disease.[7,8] Patients may have a dry cough, fever, and dyspnea. The most common presentation of COVID-19 is fever, cough and respiratory tract infection.[9] The high similarity of these clinical features between the 2 diseases presented a great challenge to accurate diagnosis and pinpoint management during the COVID-19 pandemic. Patients in DM have a high risk of infection by SARS-CoV-2. The management of COVID-19 patients with DM is not well established. Multiple research studies have found that comorbidities may increase the risk of COVID-19 patients.[10,11] Patients with DM are often immunosuppressed or immunocompromised due to the long-term use of corticosteroids and/or immunosuppressive agents.[12] Bonometti et al.[13] reported the first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Kogami et al.[14] reported a case of a patient of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Patients with DM in the first case reported, the patient gave priority to antiviral therapy and was assisted with systemic corticosteroid treatment. The second patient presented more seriously and received corticosteroid impulse and plasmapheresis therapy. The treatment of interstitial lung disease associated with DM mainly includes immunosuppression, physical therapy, monitoring, and prevention of complications.[15] Drug treatment includes corticosteroids, azathioprine, cyclophosphamide, methotrexate, biologic agents, and so on.[16] Corticosteroids are considered the mainstay of clinical management and first-line therapy of interstitial lung disease associated with DM.[17–18] If treatments continue to be ineffective after 3 to 6 months of corticosteroids, or if the patient relapses, another immunosuppressant is usually added. Corticosteroids are not recommended as a priority treatment in the management of COVID-19. The role of corticosteroids is highly disputed to treat severe infections.[19–21] Guidelines from the World Health Organization (WHO) do not recommend reliance on corticosteroids as a routine treatment for the clinical management of COVID-19.[22] Corticosteroids may inhibit immune responses and pathogen clearance when suppressing lung inflammation and could lead to delayed viral clearance and worsened outcomes. A systematic review and meta-analysis of 6548 patients found that the use of corticosteroids was The patient responded significantly worse than expected with aggressive treatment. Repeated and multi-regional nucleic acid detections of COVID-19 were negative. Finally, we considered that the diagnosis of this patient was interstitial lung disease associated with anti-MDA5 DM, rather than 2019 coronavirus disease pneumonia. This deduction was substantiated by the results of antirheumatic and anti-inflammatory therapy. These case reports demonstrate that properly managing of COVID-19 infection is crucial for distinguishing between viral infection and autoimmunity. It is highly important that nucleic acid detections with COVID-19 are considered in distinguishing lung involvements of DM and COVID-19.

The treatment of patients with COVID-19 secondary to DM is also significantly different from patients with COVID-19 or DM. In the first case we reported, the patient gave priority to antiviral therapy and was assisted with systemic corticosteroid treatment. The second patient presented more seriously and received corticosteroid impulse and plasmapheresis therapy. The treatment of interstitial lung disease associated with DM mainly includes immunosuppression, physical therapy, monitoring, and prevention of complications.[15] Drug treatment includes corticosteroids, azathioprine, cyclophosphamide, methotrexate, biologic agents, and so on.[16] Corticosteroids are considered the mainstay of clinical management and first-line therapy of interstitial lung disease associated with DM.[17–18] If treatments continue to be ineffective after 3 to 6 months of corticosteroids, or if the patient relapses, another immunosuppressant is usually added. Corticosteroids are not recommended as a priority treatment in the management of COVID-19. The role of corticosteroids is highly disputed to treat severe infections.[19–21] Guidelines from the World Health Organization (WHO) do not recommend reliance on corticosteroids as a routine treatment for the clinical management of COVID-19.[22] Corticosteroids may inhibit immune responses and pathogen clearance when suppressing lung inflammation and could lead to delayed viral clearance and worsened outcomes. A systematic review and meta-analysis of 6548 patients found that the use of corticosteroids was

### Table 2.
Clinical characteristics of the patient with dermatomyositis pulmonary interstitial fibrosis in Case 2.

| Measures                        | Normal range | Mar.07  | Mar.09  | Mar.13  | Mar.15  | Mar.17  | Mar.19  | Mar.23  | Apr.01  |
|--------------------------------|--------------|---------|---------|---------|---------|---------|---------|---------|---------|
|                                 |              | Day 2   | Day 4   | Day 8   | Day 10  | Day 12  | Day 14  | Day 18  | Day 27  |
| Laboratory examinations         |              |         |         |         |         |         |         |         |         |
| White blood cells, x10^9/L      | 3.5-9.5      | 3.67    | 8.43    | 4.92    | 4.95    | 7.18    | 7.21    | 6.95    | 6.62    |
| Neutrophil counts, x10^9 /L     | 1.8-6.3      | 3.1     | 7.61    | 4.22    | 4.24    | 6.34    | 6.36    | 6.18    | 5.91    |
| Lymphocyte counts, x10^9/ L     | 1.1-3.2      | 0.33    | 0.45    | 0.38    | 0.51    | 0.48    | 0.33    | 0.4     | 0.36    |
| C-reactive protein, mg/L        | 0-10.0       | 20.63   | 0.56    | 8.33    | 1.4     | 0.5     | 15.75   | 4.27    | 6.77    |
| D-dimer, mg/L                   | 0-500        | 1.1     | 1.24    | 0.95    | -       | -       | -       | -       | -       |
| BUN, pg/mL                      | 0-100        | 10.54   | 131.5   | 22.73   | 33.73   | 11.89   | -       | -       | -       |
| Cr, μmol/L                      | 64-104       | 53.4    | 68.3    | 44      | 46.4    | 46.1    | 45.3    | 43.5    | 51.3    |
| Uric acid, μmol/L               | 208-428      | 172     | 149     | 114     | 127     | 173     | 201     | 169     | 146     |
| ESR, mm/H                       | 0-20         | 7       | 22      | 29      | 28      | 26      | -       | 29      | 1.32    |
| IL-6, pg/mL                     | 0-7          | 55.34   | 376.9   | 2.95    | -       | 9.97    | 26.74   | 3.98    | -       |
| Vital signs                      |              |         |         |         |         |         |         |         |         |
| Temperature, °C                 | 36-37        | 37.4    | 39.3    | 36.5    | 36.4    | 36.5    | 36.7    | 36.5    | 36.5    |
| Pulse, beats per minute         | 60-100       | -       | -       | -       | -       | -       | -       | -       | -       |
| Respiratory rate, breaths per minute | 16-20       | 27     | 20      | 17      | 23      | 33      | 23      | 20      | 34      |
| Blood pressure, mmHg            | 90-140/60-90 | 88/60   | 110/65  | 126/83  | -       | 115/78  | 108/77  | 124/87  | 115/68  |

**Treatments**
- Low flow oxygen therapy
- Symptomatic and supportive treatment
- Fluid resuscitation, vasopressor, shock therapy
- Antiviral therapy
- Prophylactic anticoagulation therapy (low molecular weight heparin)
- Immunotherapy (tocilizumab)
- Anti-inflammation (glucocorticoid 80 mg, once daily, iv)
- Plasma exchange

BUN = blood urea nitrogen, Cr = creatinine, ESR = erythrocyte sedimentation rate, IL-6 = Interleukin-6.
associated with higher mortality and a higher rate of secondary infection. Conversely, a recent meta-analysis of 7 randomized trials indicated that compared with usual care, systemic corticosteroids reduced mortality in critically ill hospitalized patients with COVID-19. According to clinical experience, we hold the opinion that low-dose corticosteroids are effective and safe for severe and critical patients and may play a role in improving the prognosis of COVID-19 patients with DM. Further large-scale studies are required to confirm these findings. In compiling a treatment plan, the advantages and disadvantages of corticosteroids should be taken into consideration.

4. Conclusions
This is the first article to discuss patients with DM infected by the SARS-COVID-2 and patients with interstitial pneumonia secondary to DM. Although they have similar clinical manifestations, CT scans and laboratory test results, they are very different concerning clinical treatment. Repeated SARS-CoV-2 RT-PCR test and a detailed diagnosis based on medical history are greatly important to distinguish the 2 diseases. Effective treatment should be carried out according to the individual disease characteristics of different cases.

Acknowledgement
We thank Emily Pellegrini from Dascena (San Francisco, CA, USA) for the language editing.

Author contributions
HQP and GQZ conceived the research, YMC and JRZ designed the study, interpreted data, and wrote the manuscript. TTC contributed to the acquisition of clinical data. All authors contributed to the article and approved the submitted version.

Conceptualization: Guqin Zhang, Huaqin Pan.
Data curation: Guqin Zhang, Huaqin Pan.
Formal analysis: Jingrun Zhou, Yumeng Cao.
Investigation: Tingting Cao, Yumeng Cao.
Methodology: Jingrun Zhou, Yumeng Cao.
Supervision: Guqin Zhang, Huaqin Pan.
Validation: Yumeng Cao.
Writing – original draft: Jingrun Zhou, Yumeng Cao.
Writing – review & editing: Guqin Zhang, Huaqin Pan.

References
[1] Lee P, Hseuh PR. Emerging threats from zoonotic coronaviruses—from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53:365–7.
[2] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
[3] COVID-19 Weekly Epidemiological Update. Available at: https://covid19.who.int/.
[4] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
[5] Mathai SG, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.
[6] Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.
[7] Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282–6.
[8] Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.
[9] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.
[10] Wang X, Zhou Q, He Y, et al. Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China. Eur Respir J. 2020;55:2000544.
[11] Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for disease control and prevention. JAMA. 2020;323:1239–42.
[12] Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014;16:465.
[13] Bonometti R, Sacchi MC, Stobbione P, et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24:9695–7.
[14] Kogami M, Suzuki S, Nanjo Y, et al. Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis. Rheumatol Adv Pract. 2020;4:rkaa068.
[15] Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129–37.
[16] Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol. 2011;13:311–23.
[17] Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol. 2011;13:119–30.
[18] Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30:1021–8.
[19] Annane D, Bellissant E, Bolleart PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009;301:2362–75.
[20] Investigators CS, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010;303:341–8.
[21] Annane D, Bellissant E, Bolleart PE, et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev. 2019;12:CD002243.
[22] COVID-19 Clinical management living guidance. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.
[23] Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23:99.
[24] Sterne JAC, Murphy S; Group WHOREAfC-TW, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–41.